Publications for Paul Michael Arnaboldi paul_arnaboldi@nymc.edu
Arnaboldi, P. M., Sambir, M., D'Arco, C., Peters, L. A., Seegers, J. F., Mayer, L., . . . Dattwyler, R. J. (2016). Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. Vaccine, 34(47), 5768-5776. doi:10.1016/j.vaccine.2016.09.063
Arnaboldi, P. M., Sambir, M., D'Arco, C., Peters, L. A., Seegers, J. F., Mayer, L., McCormick, A. A., & Dattwyler, R. J. (2016). Intranasal delivery of a protein subunit vaccine using a tobacco mosaic virus platform protects against pneumonic plague. Vaccine, 34(47), 5768-5776. doi:10.1016/j.vaccine.2016.09.063
Callister, S. M., Jobe, D. A., Stuparic-Stancic, A., Miyamasu, M., Boyle, J., Dattwyler, R. J., & Arnaboldi, P. M. (2016). Detection of IFN-γ secretion by T cells collected before and after successful treatment of early Lyme disease. Clinical Infectious Diseases, 62(10), 1235-1241. doi:10.1093/cid/ciw112
Arnaboldi, P. M. & Dattwyler, R. J. (2015). Cross-reactive epitopes in Borrelia burgdorferi p66. Clinical and Vaccine Immunology, 22(7), 840-843. doi:10.1128/CVI.00217-15
Arnaboldi, P. M., Sambir, M., & Dattwyler, R. J. (2014). Decorin binding proteins A and B in the serodiagnosis of Lyme disease in North America. Clinical and Vaccine Immunology, 21(10), 1426-1436. doi:10.1128/CVI.00383-14
Dattwyler, R. J., & Arnaboldi, P. M. (2014). Comparison of Lyme disease serologic assays and Lyme specialty laboratories. Clinical Infectious Diseases, 59(12), 1711-1713. doi:10.1093/cid/ciu705
Signorino, G., Arnaboldi, P. M., Petzke, M. M., & Dattwyler, R. J. (2014). Identification of OppA2 linear epitopes as serodiagnostic markers for Lyme disease. Clinical and Vaccine Immunology, 21(5), 704-711. doi:10.1128/CVI.00792-13
Arnaboldi, P. M., Seedarnee, R., Sambir, M., Callister, S. M., Imparato, J. A., & Dattwyler, R. J. (2013). Outer surface protein C peptide derived from Borrelia burgdorferi sensu stricto as a target for serodiagnosis of early Lyme disease. Clinical and Vaccine Immunology, 20(4), 474-481. doi:10.1128/CVI.00608-12
